Molecular MR Imaging of Prostate Cancer
Avan Kader, Julia Brangsch, Jan O. Kaufmann, Jing Zhao, Dilyana B. Mangarova, Jana Moeckel, Lisa C. Adams, Ingolf Sack, Matthias Taupitz, Bernd Hamm, Marcus R. Makowski
Abstract
This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.
Topics & Concepts
Molecular imagingProstate cancerMagnetic resonance imagingMedicineProstateCancerGadoliniumMagnetic resonance spectroscopic imagingPathologyRadiologyChemistryBiologyInternal medicineIn vivoOrganic chemistryBiotechnologyProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis